TITLE:
Percutaneous Intervention of CTO Lesion and Non-CTO Lesion in Patients with Coronary Chronic Total Occlusion
AUTHORS:
Binay Kumar Adhikari, Shudong Wang, Cheng Li, Yonggang Wang, Quan Liu
KEYWORDS:
Chronic Total Occlusion, Percutaneous Coronary Intervention, Clinical Efficacy
JOURNAL NAME:
World Journal of Cardiovascular Diseases,
Vol.9 No.8,
August
21,
2019
ABSTRACT: Background: With the improved lifestyle of people, the incidence of coronary artery disease is gradually increasing. Approximately 15% - 20% of patients undergoing diagnostic catheterization had one or more chronically occluded coronary arteries. Method: The patients who were diagnosed with chronic total occlusion (CTO) in our hospital within one year period have been included. They were initially divided into two groups based on angiographic reports: single vessel disease (SVD) and non-single vessel disease (non-SVD) group, then into optimal medical therapy (OMT) group, percutaneous coronary intervention (PCI) group and coronary artery bypass graft (CABG) group.Finally, PCI group is further divided into PCI of CTO lesion (CTO PCI group) and PCIof non-CTO lesion (non-CTO PCI group). Results: A total of 261 patients were enrolled as CTO patients, mean age was 62.83 years, 70.1% were male patients.The incidence rate of common risk factors was hypertension (64.4%), followed by smoking (48.3%), diabetes (34.5%) and hyperlipidaemia (27.2%).SVD, DVD and TVD were present in 39 patients (14.94%), 81 patients (31.03%)and 141 patients (54.02%) respectively. Comparing the long term efficacy, the rates of MACE and non-target vessel revascularization were higher in CTO PCI than non-CTO PCI group, and were statistically significant (p s of target vessel revascularization, CABG and all cause death were also lower in CTO PCI group, but were not statistically significant (p > 0.05). Conclusion: The rates of MACE, non-target vessel revascularization, CABG and all cause death are lower if PCI is successfully performed in CTO patients. CTO PCI success also improves quality of life, decreases myocardial ischemia induced angina, and overall improves long term efficacy.